Anti-biofilm Activity of Phage ΦKAB and Colistin Against Carbapenem Resistance Acinetobacter baumannii
DOI:
https://doi.org/10.23851/mjs.v35i2.1480Keywords:
Acinetobacter baumannii, Carbapenem resistance, Bacteriophage, Anti-biofilm, Oxacillinases genesAbstract
Background: Carbapenem-resistant A. baumannii (CRAB) bacterium is difficult to treat with available antimicrobial agents leading to use a few antibiotics such as colistin as an option for treatment. However, the use of the colistin has serious side effects and leads to developing bacterial resistance. Objective: This study aimed to determine effectiveness of phage/colistin combination to inhibit biofilm formation of CRAB. Methods: Sixty clinical A. baummanii isolates were identified with the VITEKII system and 16S rRNA gene. The antibiotic susceptibility and detection of Oxacillinases genes were tested for all isolates. Results: The antibiotic sensitivity of A. baumannii isolates showed a high resistance percentage to Ceftriaxone (CRO) with 92% (55 isolates), and Cefotiam (CTF) with 87% (52 isolates), while the lowest percent related to Colistin (CO) with 17% (10 isolates). The results of antibiotic resistance and Oxacillinases genes reported that only 14 isolates from the current study were CRAB. Phage and host A. baumannii of phage were isolated and characterized previously. Biofilm production assay of CRAB isolates were showed that among 14 isolates including the phage host: 57% (8) was weak and 43% (6) was moderate biofilm producer. Therefore, the synergistic effect of a combination ΦKAB phage in MOI (10) and Colistin with MIC=8 µg/ml against CRAB isolates was evaluated and showed complete transfer of isolates by 100 % to weak biofilm producer compared with CRAB isolates. Conclusions: Among 60 isolates of A. baumannii, most isolates were MDR 44 (73.3%) and only 14 (23.3%) isolates were CRAB that were 57% weak and 43% moderate biofilm producers. The mixture of Colistin/ΦKAB phage could inhibit and reduce biofilm forming in CRAB isolates. Overall, the present study may provide evidence on the capability of the isolated phage to serve as a novel strategy to treat infections caused by MDR A. baumannii.
Downloads
References
A. Bianco, A. Quirino, M. Giordano, V. Marano, C. Rizzo, M. C. Liberto, A. Focà, and M. Pavia, "Control of carbapenem-resistant acinetobacter baumannii outbreak in an intensive care unit of a teaching hospital in southern italy," BMC infectious diseases, vol. 16, no. 1, pp. 1-7, 2016.
L. B. Rice, "Progress and challenges in implementing the research on eskape pathogens," Infection Control & Hospital Epidemiology, vol. 31, no. S1, S7-S10, 2010.
I. M. M. Alansary and N. A. Al-Saryi, "Emergence of hypervirulent klebsiella pneumoniae isolates from some iraqi hospitals," Reviews and Research in Medical Microbiology, vol. 35, no. 2, pp. 88-96, 2024.
J. R. Alzaidi and A. S. Mohammed, "First record of dissemination of blbli-resistant from public hospitals in baghdad, iraq," The Open Microbiology Journal, vol. 16, no. 1, 2022.
L. B. Rice, "Challenges in identifying new antimicrobial agents effective for treating infections with acinetobacter baumannii and pseudomonas aeruginosa," Clinical infectious diseases, vol. 43, no. Supplement_2, S100-S105, 2006.
G. Makke, I. Bitar, T. Salloum, B. Panossian, S. Alousi, H. Arabaghian, M. Medvecky, J. Hrabak, S. MerhebGhoussoub, and S. Tokajian, "Whole-genome-sequence-based characterization of extensively drug-resistant acinetobacter baumannii hospital outbreak," MSphere, vol. 5, no. 1, pp. 10-1128, 2020. doi: 10.1128/mSphere.00934-19.
N. T. K. Nhu, N. P. H. Lan, J. I. Campbell, C. M. Parry, C. Thompson, H. T. Tuyen, N. V. M. Hoang, P. T. T. Tam, V. M. Le, and T. V. T. Nga, "Emergence of carbapenem-resistant acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern vietnam," Journal of medical microbiology, vol. 63, no. Pt 10, 2014.
A. Vahhabi, A. Hasani, M. A. Rezaee, B. Baradaran, A. Hasani, H. Samadi Kafil, F. Abbaszadeh, and L. Dehghani, "A plethora of carbapenem resistance in acinetobacter baumannii: No end to a long insidious genetic journey,"Journal of Chemotherapy, vol. 33, no. 3, pp. 137-155, 2021.
C.-R. Lee, J. H. Lee, M. Park, K. S. Park, I. K. Bae, Y. B. Kim, C.-J. Cha, B. C. Jeong, and S. H. Lee, "Biology of acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options," Frontiers in cellular and infection microbiology, vol. 7, 2017.
A. O. Javan, S. Shokouhi, Z. Sahraei, J. Salamzadeh, and S. A. Armaki, "Nephrotoxicity of high and conventional dosing regimens of colistin: A randomized clinical trial," Iranian journal of pharmaceutical research: IJPR, vol. 16, no. 2, pp. 781-790, 2017.
H. Spapen, R. Jacobs, V. Van Gorp, J. Troubleyn, and P. M. Honoré, "Renal and neurological side effects of colistin in critically ill patients," Annals of intensive care, vol. 1, no. 1, pp. 1-7, 2011.
L. Qi, H. Li, C. Zhang, B. Liang, J. Li, L. Wang, X. Du, X. Liu, S. Qiu, and H. Song, "Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in acinetobacter baumannii," Frontiers in microbiology, vol. 7, 2016.
R. Kishk, N. Soliman, N. Nemr, R. Eldesouki, N. Mahrous, A. Gobouri, E. Azab, and M. Anani, "Prevalence of aminoglycoside resistance and aminoglycoside modifying enzymes in acinetobacter baumannii among intensive care unit patients, ismailia, egypt," Infection and Drug Resistance, pp. 143-150, 2021.
S. Ibrahim, N. Al-Saryi, I. M. Al-Kadmy, and S. N. Aziz, "Multidrug-resistant acinetobacter baumannii as an emerging concern in hospitals," Molecular biology reports, vol. 48, no. 10, pp. 6987-6998, 2021.
P. Wintachai, N. Phaonakrop, S. Roytrakul, A. Naknaen, R. Pomwised, S. P. Voravuthikunchai, K. Surachat, and D. R. Smith, "Enhanced antibacterial effect of a novel friunavirus phage vwu2001 in combination with colistin against carbapenem-resistant acinetobacter baumannii," Scientific Reports, vol. 12, no. 1, pp. 1-19, 2022.
B. A. Forbes, D. F. Sahm, and A. S. Weissfeld, Study Guide for Bailey and Scott's Diagnostic Microbiology-E-Book. Elsevier Health Sciences, 2016.
L. Chen, H. Li, H. Wen, B. Zhao, Y. Niu, Q. Mo, and Y. Wu, "Biofilm formation in acinetobacter baumannii was inhibited by paβn while it had no association with antibiotic resistance," MicrobiologyOpen, vol. 9, no. 9, 2020.
J. Sambrook, E. F. Fritsch, and T. Maniatis, Molecular cloning: a laboratory manual. Cold spring harbor laboratory press, 1989.
Clinical and L. S. I. (CLSI), Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, USA, 2022, pp. 1-362.
J. Xu, X. Li, G. Kang, L. Bai, P. Wang, and H. Huang, "Isolation and characterization of abtj, an acinetobacter baumannii phage, and functional identification of its receptor-binding modules," Viruses, vol. 12, no. 2, 2020.
E. Babapour, A. Haddadi, R. Mirnejad, S.-A. Angaji, and N. Amirmozafari, "Biofilm formation in clinical isolates of nosocomial acinetobacter baumannii and its relationship with multidrug resistance," Asian Pacific Journal of Tropical Biomedicine, vol. 6, no. 6, pp. 528-533, 2016.
C. A. N. da Rocha, "Persistence and dispersion of acinetobacter spp. in the urban water cycle," Ph.D. dissertation, Universidade do Minho (Portugal), 2010.
T. Morovat, F. Bahram, E. Mohammad, S. Setareh, and F. Mohamad Mehdi, "Emergence of carbapenem-resistant acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern vietnam," The new microbiologica, vol. 32, no. 3, 2009.
N. Woodford, M. J. Ellington, J. M. Coelho, J. F. Turton, M. E. Ward, S. Brown, S. G. Amyes, and D. M. Livermore, "Multiplex pcr for genes encoding prevalent oxa carbapenemases in acinetobacter spp.," International journal of antimicrobial agents, vol. 27, no. 4, pp. 351-353, 2006.
R. Esaa, E. Naji, and H. S. Awayid, "Comparison of three diagnostic methods for acinetobacterbaumannii hospitals," 2016.
A. Grochowalska, M. Kozioł-Montewka, and A. Sobieszczańska, "Analysis of acinetobacter baumannii resistance patterns in patients with chronic obstructive pulmonary disease (copd) in terms of choice of effective empiric antibiotic therapy," Annals of Agricultural and Environmental Medicine, vol. 24, no. 2, 2017.
C. L. Tooke, P. Hinchliffe, E. C. Bragginton, C. K. Colenso, V. H. Hirvonen, Y. Takebayashi, and J. Spencer, "β-lactamases and β-lactamase inhibitors in the 21st century," Journal of molecular biology, vol. 431, no. 18, pp. 3472-3500, 2019.
W. El-Kazzaz, L. Metwally, R. Yahia, N. Al-Harbi, A. El-Taher, and H. F. Hetta, "Antibiogram, prevalence of oxa carbapenemase encoding genes, and rapd-genotyping of multidrug-resistant acinetobacter baumannii incriminated in hidden community-acquired infections," Antibiotics, vol. 9, no. 9, 2020.
A. Hamzeh, P. Rezaee, and M. Mohammadi, "Acinetobacter baumannii antibiotics resistance in iran," J Bacteriol Mycol, vol. 7, no. 6, pp. 159-162, 2019.
R. Aziz and S. S. Al-Jubori, "Characterization of biofilm production and quorum sensing phenomenon among antibiotic resistant acinetobacter baumannii isolated from wound in fections in iraq," Journal of Global Pharma Technology, vol. 5, no. 9, pp. 50-58, 2017.
E. E. Reheama, "Prevalence study of pgaabcd locus in clinical isolates of acinetobacter baumannii," Ph.D. dissertation, College of Science. Mustansiriyah University, 2022.
H. Kadhom and M. Ali, "Epidemiological molecular analysis of acinetobacter baumannii isolates using a multilocus sequencing typing and global lineage," Revis Bionatura, vol. 7, no. 1, 2022.
H. R. Tawfeeq, M. N. Rasheed, R. H. Hassan, M. H. Musleh, and M. I. Nader, "Molecular detection of blaoxa genes in acinetobacter baumannii collected from patients with various infections," Biochem. Cell. Arch, vol. 20, no. 1, pp. 1233-1239, 2020.
Z. Li, Z. Ding, Y. Liu, X. Jin, J. Xie, T. Li, Z. Zeng, Z. Wang, and J. Liu, "Phenotypic and genotypic characteristics of biofilm formation in clinical isolates of acinetobacter baumannii," Infection and drug resistance, pp. 2613-2624, 2021.
M. S. Ramirez and M. E. Tolmasky, "Aminoglycoside modifying enzymes," Drug resistance updates, vol. 13, no. 6, pp. 151-171, 2010.
S. Upadhyay, A. B. Khyriem, P. Bhattacharya, A. Bhattacharjee, and S. R. Joshi, "High-level aminoglycoside resistance in acinetobacter baumannii recovered from intensive care unit patients in northeastern india," Indian Journal of Medical Microbiology, vol. 36, no. 1, pp. 43-48, 2018.
A. Abdi-Ali, S. Hendiani, P. Mohammadi, and S. Gharavi, "Assessment of biofilm formation and resistance to imipenem and ciprofloxacin among clinical isolates of acinetobacter baumannii in tehran," Jundishapur journal of microbiology, vol. 7, no. 1, 2014.
A. Ardebili, A. R. Lari, and M. Talebi, "Correlation of ciprofloxacin resistance with the adeabc efflux system in acinetobacter baumannii clinical isolates," Annals of laboratory medicine, vol. 34, no. 6, 2014.
E. Babapour, A. Haddadi, R. Mirnejad, S.-A. Angaji, and N. Amirmozafari, "Biofilm formation in clinical isolates of nosocomial acinetobacter baumannii and its relationship with multidrug resistance," Asian Pacific Journal of Tropical Biomedicine, vol. 6, no. 6, pp. 528-533, 2016.
E. Al-Mash'hadani, "Study the activity of bacteriocin produced from lactobacillus plantarum on virulence factors of acinetobacter baumannii," Ph.D. dissertation, 2010.
A. R. Ganjo, D. M. Maghdid, I. Y. Mansoor, D. J. Kok, J. A. Severin, H. A. Verbrugh, D. Kreft, M. Fatah, A. Alnakshabandi, and A. Dlnya, "Oxa-carbapenemases present in clinical acinetobacter baumannii-calcoaceticus complex isolates from patients in kurdistan region, iraq," Microbial drug resistance, vol. 22, no. 8, pp. 627-637, 2016.
M. M. Shalaby, M. S. Meseehah, A. M. Shahin, A. M. Abdelwahaab, and S. S. Maklad, "Phenotypic and genotypic characterization of acinetobacter infection in intensive care units in egypt," Journal of American Science, vol. 12, no. 7, pp. 99-109, 2016.
R. Tewari, D. Chopra, R. Wazahat, S. Dhingra, and M. Dudeja, "Antimicrobial susceptibility patterns of an emerging multidrug resistant nosocomial pathogen: Acinetobacter baumannii," The Malaysian journal of medical sciences: MJMS, vol. 25, no. 3, 2018.
R. Xie, X. D. Zhang, Q. Zhao, B. Peng, and J. Zheng, "Analysis of global prevalence of antibiotic resistance in acinetobacter baumannii infections disclosed a faster increase in oecd countries," Emerging microbes & infections, vol. 7, no. 1, pp. 1-10, 2018.
M. E. Falagas and S. K. Kasiakou, "Toxicity of polymyxins: A systematic review of the evidence from old and recent studies," Critical care, vol. 10, no. 1, pp. 1-13, 2006.
S. Dekic, J. Hrenovic, E. Van Wilpe, C. Venter, and I. Goic-Barisic, "Survival of emerging pathogen acinetobacter baumannii in water environment exposed to different oxygen conditions," Water Science and Technology, vol. 80, no. 8, pp. 1581-1590, 2019.
S. Brown and S. Amyes, "The sequences of seven class d β-lactamases isolated from carbapenem-resistant acinetobacter baumannii from four continents," Clinical microbiology and infection, vol. 11, no. 4, pp. 326-329, 2005.
Y.-T. Lee, J. Turton, T.-L. Chen, R. C.-C. Wu, W.-C. Chang, C.-P. Fung, C.-P. Chen, W.-L. Cho, L.-Y. Huang, and L.-K. Siu, "First identification of bla oxa-51-like in non-baumannii acinetobacter spp.," Journal of Chemotherapy, vol. 21, no. 5, pp. 514-520, 2009.
J. F. Turton, N. Woodford, J. Glover, S. Yarde, M. E. Kaufmann, and T. L. Pitt, "Identification of acinetobacter baumannii by detection of the bla oxa-51-like carbapenemase gene intrinsic to this species," Journal of clinical microbiology, vol. 44, no. 8, pp. 2974-2976, 2006.
R. Paton, R. Miles, J. Hood, and S. Amyes, "Ari 1: β-lactamase-mediated imipenem resistance in acinetobacter baumannii," International journal of antimicrobial agents, vol. 2, no. 2, pp. 81-87, 1993.
C. Héritier, L. Poirel, T. Lambert, and P. Nordmann, "Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in acinetobacter baumannii," Antimicrobial agents and chemotherapy, vol. 49, no. 8, pp. 3198-3202, 2005.
X. Wang, Z. Zong, and X. Lü, "Tn2008 is a major vehicle carrying blaoxa-23 in acinetobacter baumannii from china," Diagnostic microbiology and infectious disease, vol. 69, no. 2, pp. 218-222, 2011.
L. Poirel, S. Marqué, C. Héritier, C. Segonds, G. Chabanon, and P. Nordmann, "Oxa-58, a novel class d β-lactamase involved in resistance to carbapenems in acinetobacter baumannii," Antimicrobial agents and chemotherapy, vol. 49, no. 1, pp. 202-208, 2005.
D. Hammoudi Halat and C. A. Moubareck, "The current burden of carbapenemases: Review of significant properties and dissemination among gram-negative bacteria," Antibiotics, vol. 9, no. 4, 2020.
P. Bogaerts, T. Naas, F. El Garch, G. Cuzon, A. Deplano, T. Delaire, T.-D. Huang, B. Lissoir, P. Nordmann, and Y. Glupczynski, "Ges extended-spectrum β-lactamases in acinetobacter baumannii isolates in belgium," Antimicrobial agents and chemotherapy, vol. 54, no. 11, pp. 4872-4878, 2010.
P. Wintachai, N. Phaonakrop, S. Roytrakul, A. Naknaen, R. Pomwised, S. P. Voravuthikunchai, K. Surachat, and D. R. Smith, "Enhanced antibacterial effect of a novel friunavirus phage vwu2001 in combination with colistin against carbapenem-resistant acinetobacter baumannii," Scientific Reports, vol. 12, no. 1, 2022.
M. Jansen, A. Wahida, S. Latz, A. Krüttgen, H. Häfner, E. M. Buhl, K. Ritter, and H.-P. Horz, "Enhanced antibacterial effect of the novel t4-like bacteriophage karl-1 in combination with antibiotics against multi-drug resistant acinetobacter baumannii," Scientific reports, vol. 8, no. 1, 2018.
A. M. Comeau, F. Tétart, S. N. Trojet, M.-F. Prère, and H. Krisch, "Phage-antibiotic synergy (pas): β-lactam and quinolone antibiotics stimulate virulent phage growth," Plos one, vol. 2, no. 8, 2007.
Downloads
Key Dates
Received
Revised
Accepted
Published
Data Availability Statement
None
Issue
Section
License
Copyright (c) 2024 Kareema Ali Bahr, Ban O. Abdulsattar, Susan A. Ibrahim, Ashraf A. Abd EL-Tawab
This work is licensed under a Creative Commons Attribution 4.0 International License.
(Starting May 5, 2024) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
How to Cite
